Home World News First Mature Estimation of Median OS for Selpercatinib in Patients with RET... World News First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 899 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Clinical Trials in Genitourinary Cancers: TALAPRO-2, KEYNOTE-905, and COSMIC-313 July 9, 2020 New study to detect oesophageal cancer earlier April 28, 2022 New Drug Regimen Cures More Children with Aggressive B-Cell Lymphoma July 1, 2020 Visits to Online Breast Cancer Communities Could Help Policy Makers and... February 11, 2021 Load more HOT NEWS FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial... Risk Tool Predicts Severe Chemotherapy Toxicity in Elderly Patients with Early... EMA’s Safety Committee Has Concluded That the Benefits of Ifosfamide Solutions... Veteran Avoided The Barber For 6 Years After He Left The...
